Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 3/20 | 0.58 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5479984 | 0.82 | CARM1 (0.56) | KDM4AKDM4CNPC1RAB9AKMT2A | |
| SCHEMBL3106474 | 0.79 | RAB9A (0.53) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL8547157 | 0.76 | SIGMAR1 (0.58) | KDM4AKDM4CNPC1RAB9AALDH1A1 | |
| SCHEMBL11273441 | 0.74 | ALDH1A1 (0.57) | NPC1RAB9AKMT2AALDH1A1CA12 | |
| SCHEMBL10150374 | 0.74 | ALDH1A1 (0.57) | NPC1RAB9AKMT2AALDH1A1CA12 | |
| SCHEMBL304452 | 0.73 | RAB9A (0.55) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL13888848 | 0.73 | RAB9A (0.51) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL8189756 | 0.73 | ALOX5 (0.62) | NPC1RAB9AKMT2AALDH1A1ALOX5 | |
| Hydrochloric Acid SCHEMBL5760483 | 0.72 | RAB9A (0.53) | KDM4AKDM4CNPC1RAB9AKMT2A | |
| SCHEMBL6444116 | 0.72 | RAB9A (0.53) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871789-B2 | Method of preventing or treating viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | KDM1B, KDM1A, KDM2A | KDM4A 9/4885KDM4C 20/4885NPC1 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.